Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490850 | 0.87 | MAPK14 (0.47) | TGFBR1MAPK14MTOR | |
| SCHEMBL5497235 | 0.86 | TGFBR1 (0.70) | TGFBR1MAPK14PRKD1MAPK13MAPK12 | |
| SCHEMBL5497047 | 0.85 | TGFBR1 (0.54) | TGFBR1MAPK14PRKD1MAPK13MAPK12 | |
| SCHEMBL5139077 | 0.85 | TGFBR1 (0.56) | TGFBR1MAPK14PRKD1MAPK13MAPK12 | |
| SCHEMBL4481445 | 0.82 | TGFBR1 (0.53) | TGFBR1MAPK14PRKD1MTOR | |
| SCHEMBL5138611 | 0.79 | MAPK14 (0.51) | TGFBR1MAPK14PRKD1MAPK13MAPK12 | |
| SCHEMBL4490514 | 0.78 | TGFBR1 (0.48) | TGFBR1MAPK14PRKD1MTOR | |
| SCHEMBL4486059 | 0.78 | TGFBR1 (0.49) | TGFBR1MAPK14MTOR | |
| SCHEMBL5503286 | 0.78 | TGFBR1 (0.74) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5500967 | 0.77 | MAPK14 (0.49) | TGFBR1MAPK14PRKD1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088037-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2007-04-19 | — | — | US | claimed |
| US-7635702-B2 | Imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070088037-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-7153872-B2 | Imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-12-26 | — | — | US | disclosed |
| CN-1681805-A | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER PROD INC (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542990-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| WO-2004026859-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, TGFBR2 | TGFBR1 2/4885MAPK14 290/4885PRKD1 1406/4885 |
| US-20070088037-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885MAPK14 315/4885PRKD1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.